Newco Akribion Therapeutics GmbH has raised €8 million (US$8.3 million) in a seed round to develop a new and potent class of RNA-targeted CRISPR nucleases, which, rather than cleaving specific nucleic ...
Curently the only available blood test to tell which women are at risk of postpartum depression (PPD) is the one that ...
Aussie radiopharma company Advancell Co. Ltd. closed an oversubscribed $112 million series C round that will accelerate clinical development of its pipeline of radionuclide therapies and allow it to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results